SV-201

SV-201 is a preclinical-stage biologic candidate developed by Kangweizhonghe Biopharmaceutical that targets the Human Epidermal Growth Factor Receptor 2 (HER2). HER2 is a member of the epidermal growth factor receptor (EGFR) family and is frequently overexpressed in various malignancies, including breast, gastric, and ovarian cancers, where it promotes cell proliferation and survival. SV-201 is intended for the treatment of HER2-positive tumors, though its specific modality (e.g., monoclonal antibody or antibody-drug conjugate) has not been publicly disclosed in detail. The developer, Kangweizhonghe Biopharmaceutical, focuses on the discovery and development of recombinant proteins and other biologics for oncology and infectious diseases.